Bo Jesper Hansen proposed as new Chairman of the Board

STOCKHOLM - April 10, 2013. The Nomination Committee proposes Bo Jesper Hansen to be appointed Chairman of the Board of Karolinska Development at the Annual General Meeting on May 14, 2013.

The Nomination Committee proposes election of Bo Jesper Hansen as new member of the Board at the 2013 AGM. The Nomination Committee further proposes that Bo Jesper Hansen will succeed Hans Wigzell as the new Chairman of the Board as of 1 October 2013. Hans Wigzell is proposed to remain as ordinary Board member from the corresponding date. The Nominating Committee believes that the smooth transition provides benefits for the Board, the Company and its shareholders as it allows for Bo Jesper Hansen to gain understanding of the company's business, while the current Chairman Hans Wigzell's sound knowledge and long experience is used in the best way.

Bo Jesper Hansen has long experience in the field of international contract negotiation and deal-making, including execution of high-impact license agreements and significant M&A transactions, international marketing, extensive knowledge of legislative conditions, pharmacosurveillance, medical marketing and business development. He has extensive experience from board work and a well-developed network within the pharmaceutical industry. Currently he is Chairman of the Board at Swedish Orphan Biovitrum AB and Executive Chairman of the Board at TopoTarget A/S. He also serves as a board member of a few other companies within the pharmaceutical industry. Bo Jesper Hansen is a Doctor of Medicine and has an M.D. and a Ph.D. from University of Copenhagen.

The members of the Nomination Committee are Gillis Cullin (chairman), Rune Fransson, Peter Lundkvist, Claes Kinell and Todd Plutsky. The full proposal of the Nomination Committee will be made public by April 11, 2013.

For further information, please contact:
Gillis Cullin, Chairman of the Nomination Committee

Phone: +46 (0)73 708 88 44, e-mail: gillis.cullin@bkanold.se

Benjamin Nordin, IRO, Karolinska Development AB
Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com


TO THE EDITORS

About Karolinska Development AB
Karolinska Development aims to create value for patients, researchers, and investors by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 34 projects, of which 15 are in clinical development. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

About Us

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations.

Subscribe

Documents & Links